Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 2/20 | 0.33 |
| ▸ | GSR | P00390 | 2/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 6/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800631 | 0.85 | ALDH1A1 (0.39) | PAOXKDM4AKDM4CDNM1KDM5A | |
| SCHEMBL26730085 | 0.81 | ALDH1A1 (0.48) | PAOXKDM4AKDM4CDNM1KDM5A | |
| SCHEMBL19911169 | 0.81 | CA12 (0.32) | — | |
| SCHEMBL24811376 | 0.80 | HTR2A (0.36) | — | |
| SCHEMBL17035919 | 0.78 | CHRM1 (0.35) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL25983563 | 0.78 | UBE2N (0.38) | UBE2NMAPTCHRNB2CHRNA4CHRM2 | |
| SCHEMBL19543007 | 0.77 | MEN1 (0.40) | CHRM2CHRM1CHRM3 | |
| SCHEMBL278948 | 0.77 | — | — | |
| SCHEMBL13588704 | 0.77 | KMT2A (0.39) | MAPTCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL328029 | 0.77 | KMT2A (0.39) | CHRM1PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606030-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | Indoco Remedies Limited (IN) | 2013-06-26 | — | — | EP | claimed |
| WO-2012023147-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2012-02-23 | — | — | WO | claimed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-11 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| WO-2022133480-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-1282589-A2 | METHOD FOR PRODUCING DICARBONYL COMPOUNDS | Lonza AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001090036-A2 | METHOD FOR PRODUCING DICARBONYL COMPOUNDS | LONZA AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| EP-0693475-B1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | GRUENENTHAL GMBH (DE) | 1998-02-11 | — | — | EP | disclosed |
| EP-0176049-A2 | Aminoalkylnaphtalene derivatives having pharmacological activities | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | UBE2N 2837/4885MAPT 4280/4885CHRNB2 1107/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | UBE2N 2535/4885MAPT 3361/4885CHRNB2 4679/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | UBE2N 2535/4885MAPT 3361/4885CHRNB2 4679/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | UBE2N 3648/4885MAPT 4065/4885CHRNB2 4742/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | UBE2N 3648/4885MAPT 4065/4885CHRNB2 4742/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | UBE2N 2535/4885MAPT 3361/4885CHRNB2 4679/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | UBE2N 37/4885MAPT 1742/4885CHRNB2 1550/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | UBE2N 2063/4885MAPT 2300/4885CHRNB2 4719/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | UBE2N 219/4885MAPT 1694/4885CHRNB2 3528/4885 |
| US-20230144824-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | UBE2N 4280/4885MAPT 3321/4885CHRNB2 2977/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | UBE2N 3648/4885MAPT 4065/4885CHRNB2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.